Journal Mobile Options
Table of Contents
Vol. 84, No. 5, 2009
Issue release date: November 2009
Pharmacology 2009;84:276–281

Clinical Equivalence of Controlled-Release Oxycodone 20 mg and Controlled-Release Tramadol 200 mg after Surgery for Breast Cancer

Kampe S. · Wolter K. · Warm M. · Dagtekin O. · Shaheen S. · Landwehr S.
aDepartment of Anesthesiology and Pain Therapy, Ruhrlandklinik, University of Essen, Essen, bCenter of Communication and Information Technology, and Departments of cGynecology and dAnesthesiology and Intensive Care Medicine, University of Cologne, Cologne, Germany

Individual Users: Register with Karger Login Information

Please create your User ID & Password

Contact Information

I have read the Karger Terms and Conditions and agree.

To view the fulltext, please log in

To view the pdf, please log in


Aims: To assess clinical equivalence of 20 mg controlled-release oxycodone (Oxygesic®; Mundipharma, Limburg, Germany) and 200 mg controlled-release tramadol (Tramal long®; Grünenthal, Aachen, Germany) on a 12-hour dosing schedule in a randomized, double-blinded study of 54 ASA I–III physical status (American Society of Anesthesiologists classification of physical status) patients undergoing surgery for breast cancer. Methods: General anesthesia using remifentanil and propofol was performed for surgery. Patients were randomly allocated to 2 groups, receiving either 20 mg controlled-release oxycodone (Oxy group) or 200 mg controlled-release tramadol (Trama group) with the premedication (7.5 mg midazolam) and again 12 hours later. All patients had access to rescue medication (i.v. paracetamol). The primary variables for clinical equivalence were the differences between the mean values for pain scores at rest and pain scores on coughing over 24 hours after operation. The equivalence margin was determined as ±10 on the visual analogue scale. Results: Fifty-four patients were enrolled. Regarding pain scores at rest, the 90% CI of the mean differences between the treatment groups over 24 hours after operation was found to be within the predefined equivalence margin [–4.5 to +1.7], and the CI values for pain scores on coughing [–6.2 to +1.7] were similar. Cumulative paracetamol given over the 24-hour observation period did not differ significantly between the Oxy group (1.32 ±1.9 g) and the Trama group (1.61 ± 1.1 g; p = 0.32). There were no significant differences between the treatment groups regarding adverse events such as nausea (p = 0.13), vomiting (p = 0.24) and itching (p = 0.77). Also, no differences were found concerning patient satisfaction scores (p = 0.8) or patients’ general perception of postoperative pain management (p = 0.71). Conclusion: 20 mg controlled-release oxycodone is clinically equivalent to 200 mg controlled-release tramadol for postoperative analgesia after surgery for breast cancer.

Copyright / Drug Dosage

Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher or, in the case of photocopying, direct payment of a specified fee to the Copyright Clearance Center.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in goverment regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.


  1. Falk E: Eukodal, ein neues Narkotikum. MMW Münch Med Wochenschr 1917;20:381–384.
  2. Bruera E, Belzile M, Pituskin E, Fainsinger R, Drake A, Harsani Z, Babul N, Ford I: Randomized, double-blind, cross-over trial comparing safety and efficacy of oral controlled-release oxycodone with controlled-release morphine in patients with cancer pain. J Clin Oncol 1998;85:407–410.
  3. Kaplan R, Parris WCV, Citron ML, Zhukovsky DS, Khojasteh A, Buckley BJ, Tan C, Reder RF, Kaiko RF: Comparison of controlled-release and immediate-release oxycodone tablets in patients with cancer pain. J Clin Oncol 1998;16:3230–3237.
  4. Levy M: Advancement of opioid analgesia with controlled-release oxycodone. Eur J Pain 2001;5:113–116.
  5. Sunshine A, Olson NZ, Colon A, Rivera A, Kaiko RF, Fitzmartin RD, Reder RF, Goldenheim PD: Analgesic efficacy of controlled-release oxycodone in postoperative pain. Clin Pharmacol 1996;36:595–603.
  6. Mandema JW, Kaiko RF, Oshlack B, Reder RF, Stanski DR: Pharmacokinetic characterization of controlled-release oxycodone. Br J Clin Pharmacol 1996;42:747–756.
  7. Reuben SS, Connelly NR, Maciolek H: Postoperative analgesia with controlled-release oxycodone for outpatient anterior cruciate ligament surgery. Anesth Analg 1999;88:1286–1291.
  8. Reuben SS, Steinberg RB, Maciolek H: Preoperative administration of controlled-release oxycodone for the management of pain after ambulatory tubal ligation surgery. J Clin Anesth 2002;14:223–227.
  9. Mucci-LoRusso P, Bermann BS, Silberstein PT, Citron ML, Bressler L, Weinstein SM, Kaiko RF, Buckley BJ, Reder RF: Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur J Pain 1998;2:239–249.
  10. Kaufmann J, Yesiloglu S, Patermann B, Krombach J, Kiencke P, Kampe S: Controlled-release oxycodone is better tolerated than intravenous tramadol/metamizol for postoperative analgesia after retinal-surgery. Curr Eye Res 2004;28:271–275.
  11. Caldwell JR, Hale ME, Boyd RE, Hague JM, Iwan T, Shi M, Lacouture PG: Treatment of osteoarthritis pain with controlled-release oxycodone or fixed combination oxycodone plus acetaminophen added to nonsteroidal antiinflammatory drugs: a double-blind, randomized, multicenter, placebo controlled trial. J Rheumatol 1999;26:862–869.
  12. Lewis KS, Han NH: Tramadol: a new centrally acting analgesic. Am J Health System Pharm 1997;54:643–652.
  13. Scott LJ, Perry CM: Tramadol: a review of its use in perioperative pain. Drugs 2000;60:139–176.
  14. Grond S, Sablotzki A: Clinical pharmacology of tramadol. Clin Pharmacokinet 2004;43:879–923.
  15. Vickers MD, O’Flaherty D, Szekely SM, Read M, Yoshizumi J: Tramadol: pain relief by an opioid without depression of respiration. Anaesthesia 1992;47:291–296.
  16. Vickers MD, Paravicine D: Comparison of tramadol with morphine for postoperative pain following abdominal surgery. Eur J Anaesthesiol 1995;12:265–271.
  17. Radbruch L, Grond S, Lehmann KA: A risk-benefit assessment of tramadol in the management of pain. Drug Saf 1996;15:8–29.
  18. Cossmann M, Kohnen C, Langford R, McCartney C: Tolerance and safety of tramadol use: results of international studies and data from drug surveillance. Drugs 1997;53(suppl 2):50–62.
  19. Silvasti M, Svartling N, Pitkanen M, Rosenberg PH: Comparison of intravenous patient-controlled analgesia with tramadol versus morphine after microvascular breast reconstruction. Eur J Anaesthesiol 2000;17:448–455.
  20. DeLoach LJ, Higgins MS, Caplan AB, Stiff JL: The visual analog scale in the immediate postoperative period: intrasubject variability and correlation with a numeric scale. Anesth Analg 1998;86:102–106.
  21. Huson L: Statistical assessment of superiority, equivalence and non-inferiority in clinical trials. CRfocus 2001;12:1–4.
  22. Birtwhistle RV, Godwin MS, Delva MD, Casson RI, Lam M, MacDonald SE, Seguin R, Rühland L: Randomised equivalence trial comparing three month and six month follow up of patients with hypertension by family practitioners. BMJ 2004;328:204–210.
  23. Ploin D, Chapuis FR, Stamm D, Robert J, David L, Chatelain PG, Dutau G, Floret D: High dose albuterol by metered-dose inhaler plus a spacer device versus nebulization in preschool children with recurrent wheezing: a double-blind, randomized equivalence trial. Pediatrics 2000;106:311–317.
  24. Kampe S, Warm M, Kaufmann J, Hundegger S, Mellinghoff H, Kiencke P: Clinical efficacy of controlled-release oxycodone 20 mg administered on a 12-h dosing schedule on the management of postoperative pain after breast surgery for cancer. Curr Med Res Opin 2004;20:199–202.
  25. Anderson R, Saiers JH, Abram S, Schlicht C: Accuracy in equianalgesic dosing: conversion dilemmas. J Pain Symptom Manage 2001;21:397–406.
  26. Patanwala AE, Duby J, Waters D, Erstad B: Opioid conversions in acute care. Ann Pharmacother 2007;41:255–267.
  27. Lehmann KA: Tramadol for the management of acute pain. Drugs 1994;47(suppl 1):19–32.
  28. Greene WA, Concato J, Feinstein AR: Claims of equivalence in medical research: are they supported by evidence? Ann Intern Med 2000;132:715–722.
  29. Williamson A, Hoggart B: Pain: a review of three commonly used pain rating scales. J Clin Nurs 2004;14:798–804.

    External Resources

  30. Skovlund E, Bretthauer M, Grotmol T, Larsen IK, Hoff G: Sensitivity of pain rating scales in an endoscopy trial. Clin J Pain 2005;21:292–296.
  31. Myles PA, Troedel S, Boquest M, Reeves M: The pain visual analog scale: is it linear or nonlinear? Anesth Analg 1999;89:1517–1520.
  32. Myles PS, Urquhart N: The linearity of the visual analog scale in patients with severe acute pain. Anaesth Intensive Care 2005;33:54–58.
  33. Bijur PE, Silver W, Gallagher EJ: Reliability of the visual analog scale for measurement of acute pain. Acad Emerg Med 2001;8:1153–1157.
  34. Rosier EM, Iadarola MJ, Coghill RC: Reproducibility of pain measurement and pain perception. Pain 2002;98:205–216.
  35. Gaynes BL, Barkin RL: Analgesics in ophthalmic practice: a review of the oral non-narcotic agent tramadol. Optom Vis Sci 1999;76:455–461.
  36. Liukkonen K, Santanen U, Pere P, Erkola O, Rautoma P: Perioral tramadol premedication increases postoperative nausea and delays home-readiness in day-case knee arthroscopy patients. Scand J Surg 2002;91:365–368.
  37. Malonne H, Coffiner M, Sonet B, Sereno A, Vanderbist F: Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 2004;26:1774–1782.
  38. Cheville A, Chen A, McGarry L, Narcessian E: A randomized trial of controlled-release oxycodone during inpatient rehabilitation following unilateral total knee arthroplasty. J Bone Joint Surg Am 2001;83A:572–576.

    External Resources

  39. Wordliczek J, Banach M, Garlicki J, Jakowicka-Wordliczek J, Dobrogowski J: Influence of pre-or intraoperational use of tramadol (preemptive or preventive analgesia) on tramadol requirement in the early postoperative period. Pol J Pharmacol 2002;54:693–697.
  40. Thienthong S, Krisanaprakornkit W, Taesiri W, Thaninsurat N, Utsahapanich S, Klaichanad C: Two doses of oral sustained-release tramadol do not reduce pain or morphine consumption after modified radical mastectomy: a randomized, double blind, placebo-controlled trial. J Med Assoc Thai 2004;87:24–32.

    External Resources

  41. Wulf H, Neugebauer E, Maier C: Die Behandlung akuter perioperativer und posttraumatischer Schmerzen: Empfehlungen einer interdisziplinären Expertenkommission. Stuttgart, Georg Thieme Verlag, 1997.
  42. Zhukovsky DS, Walsh D, Doona M: The relative potency between high dose oral oxycodone and intravenous morphine: a case illustration. J Pain Symptom Manage 1999;18:53–55.

Pay-per-View Options
Direct payment This item at the regular price: USD 38.00
Payment from account With a Karger Pay-per-View account (down payment USD 150) you profit from a special rate for this and other single items.
This item at the discounted price: USD 26.50